EZH2, the catalytic subunit of the histone methyltransferase complex PRC2, is overexpressed and associated with poor prognosis in triple-negative breast cancer (TNBC). Although EZH2 inhibition significantly alters chromatin landscapes and gene expression, it has limited impact on the growth of TNBC models, suggesting a...
Lucas Porras, M. Carrière, Ann-Sophie Gironne et al.· Cancer Research· 0 citations
Abstract Background Clear cell renal cell carcinoma (ccRCC) is defined by constitutive pseudohypoxia driven by von Hippel-Lindau (VHL) loss, pronounced intratumoral heterogeneity, and aberrant hypervascularity, features that collectively promote tumor progression and limit therapeutic durability. Although VEGF-targeted...
B. Ulukan, O. Saatci, A. Madrigal et al.· The Oncologist· 0 citations
The “one-two punch” approach combining LOX inhibition with clinical DHODH inhibitor suppresses tumor growth in vivo in chemo-free setting and shows that inhibiting LOX generates targetable vulnerability to ferroptosis.
O. Saatci, B. Ulukan, Metin Cetin et al.· Cell Reports Medicine· 1 citation
Using single-cell transcriptomics, lysyl oxidase (LOX) is identified as a driver of ccRCC progression, selectively enriched in a hypoxia/epithelial-mesenchymal transition (EMT) gene program associated with poor outcome.
B. Ulukan, O. Saatci, A. Madrigal et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
